menu
    • menu
    [{"orgOrder":0,"company":"Gnosis by Lesaffre","sponsor":"SunWay Biotech","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Partnership","leadProduct":"Menaquinone-7","moa":"||Pregnane X receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Gnosis by Lesaffre","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gnosis by Lesaffre \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"Gnosis by Lesaffre \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"Gnosis by Lesaffre","sponsor":"NattoPharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Menaquinone-7","moa":"Pregnane X receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Gnosis by Lesaffre","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gnosis by Lesaffre \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"Gnosis by Lesaffre \/ Gnosis by Lesaffre"}]

    Find Clinical Drug Pipeline Developments & Deals by Gnosis by Lesaffre

    Menu

    Gnosis by Lesaffre

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gnosis by Lesaffre

                            France arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Gnosis by Lesaffre

                            France arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menaquinone-7,Ankascin 568-R

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : SunWay Biotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            SunWay Biotech and Gnosis Launch MenaQ7® Metabolic Featuring ANKASCIN® 568-R Ingredient

                            Details : The partnership aims to launch SunWay's inaugural product, MenaQ7® Metabolic, featuring two key active ingredients, MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            March 14, 2024

                            Lead Product(s) : Menaquinone-7,Ankascin 568-R

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : SunWay Biotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gnosis by Lesaffre

                            France arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Gnosis by Lesaffre

                            France arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menaquinone-7

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Recipient : NattoPharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma

                            Details : This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            May 25, 2021

                            Lead Product(s) : Menaquinone-7

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Recipient : NattoPharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gnosis by Lesaffre

                            France arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Gnosis by Lesaffre

                            France arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chondroitin Sulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Recipient : Azienda di Servizi alla Persona di Pavia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Non-animal Chondroitin Sulphate for Overweight Subjects With Knee Ostoarthritis.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 06, 2018

                            Lead Product(s) : Chondroitin Sulfate Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Recipient : Azienda di Servizi alla Persona di Pavia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth